Ironwood Pharmaceuticals, Inc.  

(Public, NASDAQ:IRWD)   Watch this stock  
Find more results for IRWD
15.45
-0.58 (-3.62%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.31 - 16.13
52 week 9.01 - 17.11
Open 15.98
Vol / Avg. 693,430.00/962,709.00
Mkt cap 2.25B
P/E     -
Div/yield     -
EPS -1.39
Shares 124.92M
Beta 1.45
Inst. own 110%
Apr 27, 2015
Q1 2015 Ironwood Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 11, 2015
Ironwood Pharmaceuticals Inc at Barclays Healthcare Conference - 11:15AM EDT - Add to calendar
Mar 2, 2015
Ironwood Pharmaceuticals Inc at Cowen Health Care Conference - 2:50PM EST - Add to calendar
Feb 12, 2015
Q4 2014 Ironwood Pharmaceuticals Inc Earnings Call - Webcast
Feb 12, 2015
Q4 2014 Ironwood Pharmaceuticals Inc Earnings Release
Jan 12, 2015
Ironwood Pharmaceuticals Inc at JPMorgan Healthcare Conference - Q&A Session
Jan 12, 2015
Ironwood Pharmaceuticals Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -98.88% -248.07%
Operating margin -87.00% -221.58%
EBITD margin - -205.45%
Return on average assets -44.43% -61.92%
Return on average equity -153.53% -299.14%
Employees 464 -
CDP Score - -

Address

301 Binney St
CAMBRIDGE, MA 02142-1030
United States - Map
+1-617-6217722 (Phone)
+1-617-4940480 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on creating medicines that make a difference for patients. The Company�s lead product, linaclotide provides patients and healthcare practitioners with a treatment option for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), GI disorders that affect millions of sufferers across the world. Linaclotide is available to adult men and women suffering from IBS-C, or CIC, in the United States under the trademarked name LINZESS, and to adult men and women suffering from IBS-C in the European Union (the E.U.), under the trademarked name CONSTELLA. The Company�s partner Astellas initiated a double-blind, placebo-controlled Phase III clinical trial of linaclotide in adult patients with IBS-C.

Officers and directors

Bryan E. Roberts Ph.D. Independent Chairman of the Board
Age: 47
Bio & Compensation  - Reuters
Peter M. Hecht Ph.D. Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Michael J. Higgins Chief Operating Officer
Age: 51
Bio & Compensation  - Reuters
Thomas Graney Chief Financial Officer, Senior Vice President - Finance, Corporate Strategy
Age: 49
Bio & Compensation  - Reuters
Mark G. Currie Ph.D. Senior Vice President, Chief Scientific Officer, President - Research and Development
Age: 59
Bio & Compensation  - Reuters
Thomas A. McCourt Senior Vice President - Marketing and Sales, Chief Commercial Officer
Age: 56
Bio & Compensation  - Reuters
Gina Consylman Chief Accounting Officer, Vice President, Corporate Controller
Age: 42
Bio & Compensation  - Reuters
Douglas E. Williams Ph.D. Director
Age: 56
Bio & Compensation  - Reuters
George H. Conrades Independent Director
Age: 75
Bio & Compensation  - Reuters
Joseph C. Cook Jr. Independent Director
Age: 72
Bio & Compensation  - Reuters